Cargando…

Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome

BACKGROUND: There is increased interest in combining nutritional modalities with pharmacological therapies for managing patients with diarrhea-predominant IBS (IBS-D). AIM: A randomized, double-blind, placebo-controlled study to evaluate the impact of oral serum-derived bovine immunoglobulin/protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Dale, Evans, Malkanthi, Weaver, Eric, Shaw, Audrey L., Klein, Gerald L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020402/
https://www.ncbi.nlm.nih.gov/pubmed/24833942
http://dx.doi.org/10.4137/CGast.S13200
_version_ 1782316064223264768
author Wilson, Dale
Evans, Malkanthi
Weaver, Eric
Shaw, Audrey L.
Klein, Gerald L.
author_facet Wilson, Dale
Evans, Malkanthi
Weaver, Eric
Shaw, Audrey L.
Klein, Gerald L.
author_sort Wilson, Dale
collection PubMed
description BACKGROUND: There is increased interest in combining nutritional modalities with pharmacological therapies for managing patients with diarrhea-predominant IBS (IBS-D). AIM: A randomized, double-blind, placebo-controlled study to evaluate the impact of oral serum-derived bovine immunoglobulin/protein isolate (SBI) on gastrointestinal symptom scores and quality of life (QoL) in subjects with IBS-D. METHODS: Study subjects previously diagnosed with IBS-D according to ROME II criteria were recruited from London, Ontario, Canada and assigned to receive 5 g/day SBI, 10 g/day SBI, or placebo for 6 weeks. Daily symptom frequency and severity scores and a modified IBS-36 questionnaire assessed the impact of nutritional intervention. Laboratory assessments were performed at screening and end of treatment (EOT) to evaluate safety. Within-group comparisons of changes in number of days per week with symptoms and symptom severity were conducted on the per-protocol population of subjects using a t-test. RESULTS: Subjects who received SBI at 10 g/day (N = 15) had statistically significant within-group reductions in abdominal pain (p < 0.01), loose stools (p < 0.01), bloating (p < 0.05), flatulence (p < 0.01), urgency (p < 0.05) and any symptom (p < 0.01) at EOT vs. baseline. Subjects receiving 5 g/day of SBI (N = 15) realized statistically significant within-group reductions in days with flatulence (p < 0.035), incomplete evacuation (p < 0.05), and any symptom (p < 0.01). There were no significant changes in QoL scores or in hematology or clinical chemistry among treatment groups. CONCLUSIONS: This pilot study showed that nutritional therapy with either 10 g/day or 5 g/day of SBI in 30 patients was well tolerated and resulted in statistically significant within group improvements in both symptom days and in daily symptom scores in subjects with IBS-D. Additional studies are underway with larger numbers of subjects to validate these findings.
format Online
Article
Text
id pubmed-4020402
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-40204022014-05-15 Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome Wilson, Dale Evans, Malkanthi Weaver, Eric Shaw, Audrey L. Klein, Gerald L. Clin Med Insights Gastroenterol Original Research BACKGROUND: There is increased interest in combining nutritional modalities with pharmacological therapies for managing patients with diarrhea-predominant IBS (IBS-D). AIM: A randomized, double-blind, placebo-controlled study to evaluate the impact of oral serum-derived bovine immunoglobulin/protein isolate (SBI) on gastrointestinal symptom scores and quality of life (QoL) in subjects with IBS-D. METHODS: Study subjects previously diagnosed with IBS-D according to ROME II criteria were recruited from London, Ontario, Canada and assigned to receive 5 g/day SBI, 10 g/day SBI, or placebo for 6 weeks. Daily symptom frequency and severity scores and a modified IBS-36 questionnaire assessed the impact of nutritional intervention. Laboratory assessments were performed at screening and end of treatment (EOT) to evaluate safety. Within-group comparisons of changes in number of days per week with symptoms and symptom severity were conducted on the per-protocol population of subjects using a t-test. RESULTS: Subjects who received SBI at 10 g/day (N = 15) had statistically significant within-group reductions in abdominal pain (p < 0.01), loose stools (p < 0.01), bloating (p < 0.05), flatulence (p < 0.01), urgency (p < 0.05) and any symptom (p < 0.01) at EOT vs. baseline. Subjects receiving 5 g/day of SBI (N = 15) realized statistically significant within-group reductions in days with flatulence (p < 0.035), incomplete evacuation (p < 0.05), and any symptom (p < 0.01). There were no significant changes in QoL scores or in hematology or clinical chemistry among treatment groups. CONCLUSIONS: This pilot study showed that nutritional therapy with either 10 g/day or 5 g/day of SBI in 30 patients was well tolerated and resulted in statistically significant within group improvements in both symptom days and in daily symptom scores in subjects with IBS-D. Additional studies are underway with larger numbers of subjects to validate these findings. Libertas Academica 2013-12-05 /pmc/articles/PMC4020402/ /pubmed/24833942 http://dx.doi.org/10.4137/CGast.S13200 Text en © 2013 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
spellingShingle Original Research
Wilson, Dale
Evans, Malkanthi
Weaver, Eric
Shaw, Audrey L.
Klein, Gerald L.
Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome
title Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome
title_full Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome
title_fullStr Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome
title_full_unstemmed Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome
title_short Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome
title_sort evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020402/
https://www.ncbi.nlm.nih.gov/pubmed/24833942
http://dx.doi.org/10.4137/CGast.S13200
work_keys_str_mv AT wilsondale evaluationofserumderivedbovineimmunoglobulinproteinisolateinsubjectswithdiarrheapredominantirritablebowelsyndrome
AT evansmalkanthi evaluationofserumderivedbovineimmunoglobulinproteinisolateinsubjectswithdiarrheapredominantirritablebowelsyndrome
AT weavereric evaluationofserumderivedbovineimmunoglobulinproteinisolateinsubjectswithdiarrheapredominantirritablebowelsyndrome
AT shawaudreyl evaluationofserumderivedbovineimmunoglobulinproteinisolateinsubjectswithdiarrheapredominantirritablebowelsyndrome
AT kleingeraldl evaluationofserumderivedbovineimmunoglobulinproteinisolateinsubjectswithdiarrheapredominantirritablebowelsyndrome